NCT07178678View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

December 31, 2030

Conditions
Mild Alzheimer's DiseaseModerate Alzheimer's Disease
Interventions
DRUG

NeuroEPO

0.5 mg of NeuroEPO will be administered intranasally three times a week for 52 weeks.

DRUG

Placebo

250 µL of placebo will be administered to intranasally to each nostril three times a week for 52 weeks.

Trial Locations (1)

S7N5E5

University of Saskatchewan, Saskatoon

All Listed Sponsors
collaborator

Center of Molecular Immunology, Cuba

OTHER

lead

University of Saskatchewan

OTHER